Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.37
-0.3900-2.47%
Post-market: 15.370.00000.00%19:30 EDT
Volume:1.14M
Turnover:17.53M
Market Cap:1.31B
PE:-4.03
High:15.69
Open:15.68
Low:15.23
Close:15.76
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.92
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:3.05
PE(LYR):-4.35

Loading ...

Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Apr 11

Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment

TIPRANKS
·
Apr 03

BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million

Reuters
·
Apr 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Apr 01

MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says

MT Newswires Live
·
Mar 30

MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG

Dow Jones
·
Mar 30

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)

TIPRANKS
·
Mar 30

H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Mar 30

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

TIPRANKS
·
Mar 29

MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials

Reuters
·
Mar 29

MoonLake Announces Week 40 Results From Its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 Aad Annual Meeting

THOMSON REUTERS
·
Mar 29

MoonLake Immunotherapeutics management to meet with BTIG

TIPRANKS
·
Mar 27

MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade

MT Newswires Live
·
Mar 24

MoonLake Immunotherap Raised to Outperform From Underperform by Wolfe Research

Dow Jones
·
Mar 23

MoonLake upgraded to Outperform from Underperform at Wolfe Research

TIPRANKS
·
Mar 23

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)

TIPRANKS
·
Mar 20

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase

Simply Wall St.
·
Mar 20

MoonLake Immunotherap Raised to Buy From Neutral by Rothschild & Co

Dow Jones
·
Mar 20

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

TIPRANKS
·
Mar 19

MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns

TIPRANKS
·
Mar 13